

Maruzen Pharmaceuticals Co., Ltd.
Head of Public Relations, Emergency Response Headquarters

Notice on Business Continuity Activities Following the Activation of the Business Continuity Plan (BCP)
(Fourth Report)

We would like to once again sincerely apologize to all concerned parties for the significant concern and inconvenience caused by the explosion and fire incident that occurred at our Miyoshi Factory (Miyoshi City, Hiroshima Prefecture) on April 28, 2026. We also sincerely wish a swift recovery for those who were injured.

1. Overview of the Accident

On April 28, 2026, an explosion occurred at the Miyoshi Factory during work related to the construction of a new manufacturing building. We are continuing to investigate the cause of the accident in cooperation with the relevant authorities.

2. Administrative Response and Equipment Inspection Status

Following the accident, under the guidance of the relevant authorities, inspections and confirmations have been carried out for the affected equipment and related facilities. We are proceeding step by step with safety verification while conducting the necessary inspections and reporting.

3. Resumption of Production Activities

At the Miyoshi Factory, following equipment inspections, testing, and safety verification conducted under the guidance of the relevant authorities, we are now in a position to resume basic production activities starting from May 18, 2026.

However, as restoration work on some equipment is still ongoing, individual adjustments or consultations may be required depending on the product. For the time being, operations are expected to continue under certain constraints.

In preparation for the resumption, we have confirmed the following:

- Equipment inspections and safety checks in accordance with the guidance of relevant authorities
- Equipment functionality through necessary testing and trial operations
- Proper operation of all necessary production functions, including equipment and utilities

Through these processes, we have confirmed that production activities can be carried out safely.

At present, we are in a position to resume basic production operations. However, as restoration work for certain equipment is still ongoing, we anticipate that production will resume under certain constraints for the time being.

4. Shipments and Supply Response

Shipments have been carried out since May 8 for inventory stored in warehouses where safety checks have been completed. We will continue efforts to stabilize supply, including using other company facilities and external partners.

5. Future Actions

We will continue to investigate the cause of the accident, review safety management systems as necessary, and proceed with recovery efforts.

We sincerely apologize again for the concern and inconvenience caused. We will continue to prioritize safety and work toward the early recovery of stable supply.

Contact Information for Inquiries

For inquiries regarding business continuity activities and supply responsibilities for products and services, please contact the following:

Maruzen Pharmaceuticals Co., Ltd.

TEL: +81-3-5422-3265

Please note that telephone lines may be difficult to reach due to emergency response operations.

Thank you for your understanding.